Carfilzomib Side Effects: Safety Signals and Warnings
Carfilzomib safety concerns are compound-specific. The main listed side effects are Fatigue, Anemia and thrombocytopenia, and Dyspnea. The main warning signals are Cardiac toxicity - assess cardiac function before and during treatment, Pulmonary toxicity including ARDS reported, and Tumor lysis syndrome risk - ensure adequate hydration.
Direct Answer
Carfilzomib (Kyprolis) is FDA-approved for relapsed/refractory multiple myeloma with multiple Phase 3 trials (ASPIRE, ENDEAVOR) showing significant PFS improvement. As an irreversible proteasome inhibitor, it is active against bortezomib-resistant disease and is a standard component of modern myeloma combination regimens. A well-validated oncology drug with robust Phase 3 data.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- Relapsed/refractory multiple myeloma, proteasome inhibitor pharmacology, bortezomib-resistant disease
Reported Side Effects
- Fatigue
- Anemia and thrombocytopenia
- Dyspnea
- Hypertension
- Cardiac events (heart failure, arrhythmias)
- Peripheral neuropathy (less than bortezomib)
Warnings
- Cardiac toxicity - assess cardiac function before and during treatment
- Pulmonary toxicity including ARDS reported
- Tumor lysis syndrome risk - ensure adequate hydration
- Hepatotoxicity - monitor liver function tests
- Thrombotic microangiopathy reported
Known or Plausible Interactions
- Strong CYP3A4 inhibitors (may increase carfilzomib exposure)
- Oral contraceptives (efficacy may be reduced)
- Live vaccines (avoid during immunosuppression)
Regulatory Context
FDA-approved for relapsed or refractory multiple myeloma. Available by prescription only. Administered in healthcare settings. Marketed as Kyprolis by Amgen.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Multiple Myeloma Response (Level A), Overall Survival Benefit (Level A), and Cardiac Toxicity Risk (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Carfilzomib Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/carfilzomib-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.